🇺🇸 FDA
Patent

US 8916175

Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection

granted A61KA61K39/12A61K39/25

Quick answer

US patent 8916175 (Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K39/12, A61K39/25, A61P, A61P31/12